Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

BMM vs AHR: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

AHR Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 10–0 Matrix Metrics)

AHR Overall Winner 6-Pillar Tally: BMM 0 – 5 AHR (1 Tie) Matrix Metrics: BMM 0 – 10 AHR

As of Nov 20, 2026, American Healthcare REIT, Inc. (AHR) is the stronger overall head-to-head candidate over BMM (BMM) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BMM carries a Unified Composite Score of 38.2/100 (SELL) at $2.50 (N/M Forward P/E, N/A operating margin), whereas AHR carries 44.7/100 (HOLD) at $57.54 (63.9x Forward P/E, 6.8% operating margin).

  • Technical & Structure Timing Caution: BMM is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 25.8); meanwhile AHR trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 58.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About BMM vs AHR
BMM US Equity
BMM
Institutional Equity
$2.50
-8.42% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 2.19β · 100% Vol
Unified Composite Score
38.2 / 100 SELL
Tech 25.0 Fund 39.0 Flow 50.0 Mom 34.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -16.9%), weak momentum, RSI 26
RSI-14: 25.8 · SMA20: $3.40 · SMA50: $4.28
AHR NYSE Head-to-Head Winner
American Healthcare REIT, Inc.
Real Estate Investment Trusts
$57.54
-0.12% 1D
Market Cap $13.4B
TTM Revenue $2.67B
Forward P/E 63.9x
Beta / 30D Vol 0.02β · 28% Vol
Unified Composite Score
44.7 / 100 HOLD
Tech 33.0 Fund 46.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (0.7% over 20 days), RSI 59
RSI-14: 58.7 · SMA20: $56.27 · SMA50: $53.77

6-Pillar Scorecard Institutional Category Breakdown (BMM 0 – 5 AHR)

Columns: Metric · BMM · AHR
1. Valuation Multiples AHR
Forward P/E N/M 63.9x
Trailing P/E N/M 117.6x
PEG Ratio N/M N/M
EV / Revenue N/M 5.0x
2. Growth & Scale AHR
Revenue Growth (YoY) N/A +29.4%
Earnings Growth (YoY) N/A -57.6%
TTM Revenue (USD) N/A $2.67B
Market Cap N/A $13.4B
3. Profitability & Quality AHR
Gross Margin N/A 20.3%
Operating Margin N/A 6.8%
Net Profit Margin N/A 3.6%
Return on Equity (ROE) N/A 2.3%
4. Balance Sheet & Cash Flow AHR
Cash Generation (TTM) N/A $497M EBITDA
Cash Flow Margin N/A 18.6% EBITDA Mgn
Net Cash / Leverage N/A ROE $23.91 Book/Sh · 2.3% ROE
Dividend Yield None (0.00%) 1.71%
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) 31.1% (27th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markup
6. R&D & Supply-Chain Moat AHR
OpEx & R&D Intensity N/A 13.5% of Rev ($361M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator REIT - Healthcare Facilities Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: BMM (0) vs AHR (10)
Institutional Metric BMM AHR Criterion Row Edge
Market Capitalization
Scale
N/A $13.4B Larger Scale AHR
Trailing P/E Ratio
Valuation
N/M 117.6x Lower Multiple AHR
Forward P/E Ratio
Valuation
N/M 63.9x Lower Multiple AHR
Revenue Growth (YoY)
Growth
N/A +29.4% Higher Growth AHR
Operating Margin (TTM)
Profitability
N/A 6.8% Higher Margin AHR
Net Profit Margin
Profitability
N/A 3.6% Higher Margin AHR
Return on Equity (ROE)
Capital Efficiency
N/A 2.3% Higher ROE AHR
52-Week Range Position
Momentum
0% ($2–$9) 86% ($45–$60) Stronger Trend AHR
Beta / 30D Volatility
Risk Regime
2.19β · 100% Vol 0.02β · 28% Vol Lower Realized Risk AHR
Unified Institutional Score
Composite Signal
38.2 / 100 (SELL) 44.7 / 100 (HOLD) Higher Composite AHR
Trailing 12M Revenue (USD)
Operating Scale
N/A $2.67B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 20.3% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 5.0x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) $497M EBITDA ($23.91 Book/Sh · 2.3% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon AHR +44.3 pp
BMM: -36.55% · AHR: +7.75%
3M Horizon AHR +55.32 pp
BMM: -52.92% · AHR: +2.4%
6M Horizon AHR +79.63 pp
BMM: -64.99% · AHR: +14.64%
1Y Horizon AHR +69.15 pp
BMM: -44.69% · AHR: +24.46%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BMM vs AHR. Trailing 12-month operating profitability (BMM N/A vs AHR 6.8%) and valuation multiples (BMM N/M vs AHR 63.9x Forward P/E) are benchmarked directly in Pillar 4 below.

BMM ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
AHR ADR TTM Benchmark FX-Normalized USD
TTM Revenue$2.67B
Gross Margin20.3%
Op. Margin6.8%
ROE / Fwd P/E2.3% · 63.9x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
BMM UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BMM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
AHR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 31.1%
IV Percentile 27th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AHR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
BMM Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
AHR Moat Profile Cyclical / Execution-Driven Positioning
REIT - Healthcare Facilities Operator
Competes within the REIT - Healthcare Facilities value chain with $13.4B market capitalization and 6.8% operating margin.
OpEx & R&D Reinvestment 13.5% of Rev ($361M)
90D Engineering Disclosures 0 Published

Investor FAQ BMM vs AHR Key Questions & Quantitative Answers

As of Nov 20, 2026, American Healthcare REIT, Inc. (AHR) is the stronger overall head-to-head candidate over BMM (BMM) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BMM carries a Unified Composite Score of 38.2/100 (SELL) at $2.50 (N/M Forward P/E, N/A operating margin), whereas AHR carries 44.7/100 (HOLD) at $57.54 (63.9x Forward P/E, 6.8% operating margin). Technical & Structure Timing Caution: BMM is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 25.8); meanwhile AHR trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 58.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

AHR leads the Growth & Scale pillar: BMM posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with AHR at +29.4% YoY revenue growth and -57.6% YoY earnings growth on $2.67B TTM revenue (20.3% gross margin, 6.8% operating margin). On trailing 12-month operating scale, BMM generates N/A in USD-normalized revenue versus $2.67B for AHR. In operating R&D and SG&A reinvestment, BMM deploys N/A (0 90-day corporate R&D disclosures) versus 13.5% of Rev ($361M) (0 disclosures) for AHR.

AHR screens cheaper on headline valuation multiples. BMM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas AHR trades at 63.9x Forward P/E, 117.6x Trailing P/E, N/M PEG, and 5.0x EV/Revenue (18.6% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BMM (N/A ROE) versus AHR (2.3% ROE) capital efficiency.

In options market volatility and institutional positioning, BMM carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.19β · 100% Vol realized risk). By comparison, AHR carries 31.1% implied volatility (27th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.02β · 28% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.